Genomics

Dataset Information

0

Gene expression of SARS-CoV-2-infected Vero E6 cells


ABSTRACT: We conducted a high-throughput drug repositioning screen using the LOPAC®1280 and the ReFRAME drug libraries to identify existing drugs that harbor antiviral activity against SARS-CoV-2, in a Vero E6 cell-based assay. We additionally performed RNA sequencing on control and SARS-CoV-2 infected Vero E6 cells to study the biological changes after SARS-CoV-2 infection and to elucidate the potential mechanisms underlying the positive hits identified from our high-throughput screen. Vero E6 cells were either mock-infected or infected with SARS-CoV-2 USA-WA1/2020 (MOI = 0.3) with three replicates. Cells were harvested 24 hours after infection, and total RNA was extracted using the Qiagen® RNeasy® Plus Mini Kit. The quality of the extracted RNA was assessed with the Agilent® 2100 Bioanalyzer. Libraries were prepared from total RNA following ribosome RNA depletion using standard protocol according to Illumina®. Total RNA sequencing was then performed on the Illumina® NextSeq system; 150bp paired-end runs were performed and 100 million raw reads per sample were generated.

ORGANISM(S): Chlorocebus sabaeus Severe acute respiratory syndrome coronavirus 2

PROVIDER: GSE153940 | GEO | 2020/07/08

REPOSITORIES: GEO

Similar Datasets

2021-02-02 | GSE165955 | GEO
2021-03-23 | GSE169370 | GEO
2015-11-19 | E-GEOD-56193 | biostudies-arrayexpress
2020-11-21 | GSE161881 | GEO
2021-07-29 | PXD021154 | Pride
2021-07-29 | PXD021403 | Pride
2021-07-29 | PXD021153 | Pride
2020-05-29 | PXD018804 | Pride
2020-06-03 | PXD018594 | Pride
2020-07-15 | PXD019645 | Pride